title: Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility.
authors.affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, MI norahh@med.umich.edu.
authors.forename: N Lynn
authors.initials: NL
authors.lastname: Henry
authors.affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
authors.forename: Anne F
authors.initials: AF
authors.lastname: Schott
authors.affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Hayes
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D058534:Class I Phosphatidylinositol 3-Kinases; D005260:Female; D006801:Humans; D009154:Mutation; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D058534:Class I Phosphatidylinositol 3-Kinases; D019869:Phosphatidylinositol 3-Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; C484760:PIK3CA protein, human; C508053:ERBB2 protein, human